Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours from China's Alphamab in a deal worth up to $2.2 billion, and partnering with AstraZeneca on a breast cancer candidate. In China, JSKN016 is in phase 3 testing for triple-negative breast cancer (TNBC), with earlier-stage studies on the go in HER2-negative breast cancer, lung cancer, and other TROP2- and HER3-expressing solid tumour types. The deal with AZ – terms of which have not been disclosed – will see Pathos take responsibility for early clinical development of AZD4241, a PROTAC (proteolysis-targeting chimaera) targeting the oestrogen receptor that is currently in preclinical testing. The drug will be developed for HR-positive, HER2-negative breast cancer. Rounding out its current R&D portfolio is MET kinase inhibitor DO-2, in early clinical development for MET-altered non-small-cell lung cancer (NSCLC), which originates from Pathos' acquisition of a majority stake in Belgian biotech DeuterOncology in May.